Earlier, SMBC Nikko analyst David Hoang initiated coverage of Sarepta with an Outperform rating and $185 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SRPT:
- William Blair biotech analyst to hold an analyst/industry conference call
- Catalent concerns ‘may be overstated’ for Sarepta, says RBC Capital
- Sarepta sees no impact on SRP-9001 from Catalent update, says BofA
- Morgan Stanley still expects Sarepta to get approval for SRP-9001
- Sarepta approval still likely despite STAT article, says William Blair